Discovery Life Sciences, the biospecimen and biomarker specialists, completed the acquisition of the Gentest business of Corning, an American multinational technology company. Financial terms were not disclosed. "We are excited to welcome the brilliant scientific experts and exceptional talent behind Corning's Gentest portfolio to the Discovery team. Our combined decades of experience in the application of in vitro experimental approaches in the evaluation of drug metabolism, drug-drug interactions, toxicology, and pharmacology, plus our combined unparalleled technologies, allow Discovery to provide the most advanced and highest quality in vitro products and research services to the research communities and drug development laboratories," Albert Li, Discovery Chief Scientific Officer of Pharmacology and Toxicology.